Mundipharma EDO

Imbrium Therapeutics and Mundipharma EDO Announce Orphan Drug Designation for Relapsed Refractory Biliary Tract Cancer Treatment
CP Wire
Fri, 02/22/19 - 10:00 am
Imbrium Therapeutics
Mundipharma EDO
Purdue Pharma
etoposide toniribate
cholangiocarcinoma
Imbrium Therapeutics and Mundipharma EDO Announce Orphan Drug Designation for Relapsed Refractory Biliary Tract Cancer Treatment
Fri, 02/22/19 - 09:59 am
Imbrium Therapeutics
Mundipharma EDO
Purdue Pharma
etoposide toniribate
cholangiocarcinoma